Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 226

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 226
---
41)$2.72 $(3.88)Net income (loss) per share of common stock — diluted$(0.18)$(1.41)$2.68 $(3.88)

See notes to condensed consolidated financial statements. 

6

KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share data) 

(Unaudited)

COMMON STOCK$0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITY SHARESAMOUNTAs of December 31, 202440,554,705 $4 $1,140,328 $(568,779)$571,553 Exercise of common stock options7,342 — 4 — 4 Stock-based compensation— — 8,863 — 8,863 Net income (loss)— — — 148,451 148,451 As of March 31, 202540,562,047 $4 $1,149,195 $(420,328)$728,871 Exercise of common stock options53,367 — 17 — 17 Stock-based compensation— — 8,542 — 8,542 Net income (loss)— — — (30,696)(30,696)As of June 30, 202540,615,414 $4 $1,157,754 $(451,024)$706,734 Issuance of common stock under the employee stock purchase plan11,806 — 138 — 138 Exercise of common stock options4,944 — 2 — 2 Stock-based compensation— — 3,986 — 3,986 Net income (loss)— — (7,280)(7,280)As of September 30, 202540,632,164 $4 $1,161,880 $(458,304)$703,580 COMMON STOCK $0.0001 PAR VALUEADDITIONALPAID-INCAPITALACCUMULATEDDEFICITTOTAL STOCKHOLDERS’  EQUITY SHARESAMOUNTAs of December 31, 202331,841,084 $3 $713,636 $(381,426)$332,213 Issuance of common stock